NCT05934331

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Jul 27, 2023
Primary completion: Jul 1, 2025
Completion date: Jan 1, 2026
First posted: Jul 6, 2023
Last posted: Oct 6, 2023
Enrollment: 276
Arms / groups: 1 / —
Source: AACT · ctgov ingestion

Sponsors

LaNova Medicines LimitedLead sponsor
Chinese Academy of Medical SciencesOverall official - principal investigator
Chongqing Medical UniversityOverall official - principal investigator
Fudan UniversityOverall official - principal investigator
Wuhan UniversityOverall official - principal investigator
Chinese Academy of Medical SciencesOverall official - principal investigator
Huazhong University of Science and TechnologyOverall official - principal investigator
Shenzhen UniversityOverall official - principal investigator
Zhejiang UniversityOverall official - principal investigator
Wannan Medical CollegeOverall official - principal investigator
The First People's Hospital of ChangzhouOverall official - principal investigator
Tianjin Medical UniversityOverall official - principal investigator
Huazhong University of Science and TechnologyOverall official - principal investigator
Wuhan UniversityOverall official - principal investigator
Chinese Academy of Medical SciencesOverall official - principal investigator
Zhejiang UniversityOverall official - principal investigator
Zhejiang UniversityOverall official - principal investigator
Zibo City First HospitalOverall official - principal investigator
Wuhan UniversityOfficial
Tianjin Medical UniversityOfficial
Wuhan UniversityOfficial
Zibo City First HospitalOfficial
Zhejiang UniversityOfficial
Zhejiang UniversityOfficial
Zhejiang UniversityOfficial
The First People's Hospital of ChangzhouOfficial
Huazhong University of Science and TechnologyOfficial
Huazhong University of Science and TechnologyOfficial
Chinese Academy of Medical SciencesOfficial
Chongqing Medical UniversityOfficial
Chinese Academy of Medical SciencesOfficial
Chinese Academy of Medical SciencesOfficial
Shenzhen UniversityOfficial
Fudan UniversityOfficial
Wannan Medical CollegeOfficial
Shanghai Xuhui District Central HospitalOfficial
Xiamen UniversityOfficial
Nanyang Central HospitalOfficial

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.